You are here: Industry Insights > Debiopharm

News List

Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study prnasia
December 17, 2021
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123...
CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections prnasia
October 19, 2021
Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453...
Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis prnasia
October 13, 2021
Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, today announced the Indonesian launch of triptorelin...
Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients prnasia
February 25, 2021
Genome & Company today announced having entered into a research collaboration for the discovery of innovative cancer therapies in the expanding antibody-drug conjugates (ADC) class.
Phase II trial to establish whether alisporivir can prevent COVID-19 progression europeanpharmaceuticalreview
January 22, 2021
The trial will primarily assess whether alisporivir (Debio 025) can significantly reduce COVID-19 viral load in hospitalised COVID-19 patients with moderate symptoms.
Debiopharm Expands Its Radiopharmaceutical Footprint contractpharma
March 26, 2020
Exclusive license and research agreement to further develop radioligand program to fight the progression of cancer.